NASDAQ · MCRB
Healthcare · Biotechnology
$4.72
Down-$0.16 (-3.39%)
Updated Aug 13, 2026, 7:46 PM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
MCRB closed at $4.72 after 21 trading sessions, down 13.39% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $4.63 | $4.7671 | $4.585 | $4.72 | 45.37K |
| Aug 11, 2026 | $4.94 | $4.94 | $4.615 | $4.64 | 84.68K |
| Aug 10, 2026 | $5.05 | $5.05 | $4.76 | $5.00 | 84.6K |
| Aug 7, 2026 | $5.07 | $5.1894 | $4.82 | $4.87 | 62.32K |
| Aug 6, 2026 | $5.01 | $5.15 | $4.70 | $4.82 | 80.16K |
| Aug 5, 2026 | $5.63 | $5.65 | $4.82 | $5.005 | 141.75K |
| Aug 4, 2026 | $5.07 | $5.40 | $4.81 | $5.25 | 40.46K |
| Aug 3, 2026 | $4.90 | $5.13 | $4.90 | $5.03 | 29.85K |
| Jul 31, 2026 | $4.86 | $4.99 | $4.645 | $4.83 | 51.18K |
| Jul 30, 2026 | $4.77 | $4.90 | $4.60 | $4.78 | 50.38K |
| Jul 29, 2026 | $4.74 | $4.91 | $4.63 | $4.65 | 53.11K |
| Jul 28, 2026 | $4.84 | $5.01 | $4.59 | $4.80 | 63.36K |
| Jul 27, 2026 | $4.98 | $5.29 | $4.85 | $4.85 | 67.62K |
| Jul 24, 2026 | $5.22 | $5.44 | $4.92 | $4.965 | 84.53K |
| Jul 23, 2026 | $5.21 | $5.36 | $5.11 | $5.23 | 29.82K |
| Jul 22, 2026 | $5.27 | $5.33 | $5.17 | $5.28 | 28.77K |
| Jul 21, 2026 | $5.16 | $5.325 | $5.10 | $5.25 | 26.94K |
| Jul 20, 2026 | $5.36 | $5.36 | $5.00 | $5.11 | 48.94K |
| Jul 17, 2026 | $5.13 | $5.69 | $5.13 | $5.33 | 56.36K |
| Jul 16, 2026 | $5.42 | $5.5996 | $5.115 | $5.18 | 84.14K |
| Jul 15, 2026 | $5.36 | $5.54 | $5.21 | $5.45 | 30.99K |
The latest Smart Investors Daily articles mentioning MCRB.
MCRB research
Company profile and research snapshot.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 23, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 13, 2026 | Canaccord Genuity | Buy | — |
| Sep 24, 2025 | Canaccord Genuity | Buy | — |
| May 8, 2025 | Chardan Capital | Neutral | — |
| Mar 20, 2025 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 5, 2026
Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $(2.19) by 121.56 percent. This is a 120.7 percent increase over losses of $(2.27) per share
Benzinga · Jul 8, 2026
Seres Therapeutics reported early SER-155 data, with 80% of patients achieving steroid-free clinical response by Day 15.
SeekingAlpha · Jul 8, 2026
2026-07-08. The following slide deck was published by Seres Therapeutics, Inc.
SeekingAlpha · Jul 8, 2026
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis July 8, 2026 8:30 AM...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MCRB.
